Literature DB >> 26137400

Mast cell/MDSC a liaison immunosuppressive for tumor microenvironment.

Luca Danelli1, Barbara Frossi2, Carlo E Pucillo2.   

Abstract

The instauration of an immunosuppressive microenvironment is a key event in cancer development and progression. Here, we discuss increasing evidences of the crosstalk between myeloid-derived suppressor cells (MDSCs) and mast cells (MCs) as a new fuel for the cancer immunosuppressive machinery.

Entities:  

Keywords:  CD40:CD40L; colon carcinoma; immunosuppression; mast cells; myeloid derived suppressor cells

Year:  2015        PMID： 26137400      PMCID： PMC4485753          DOI： 10.1080/2162402X.2014.1001232

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses.

Authors:  Johanna K Morales; Sheinei J Saleem; Rebecca K Martin; Bryan L Saunders; Brian O Barnstein; Travis W Faber; Nicholas A Pullen; Elizabeth Motunrayo Kolawole; Keith B Brooks; Sarah K Norton; Jamie Sturgill; Laura Graham; Harry D Bear; Joseph F Urban; Chris S Lantz; Daniel H Conrad; John J Ryan
Journal:  J Leukoc Biol       Date:  2013-12-12       Impact factor: 4.962

2.  Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity.

Authors:  Sheinei J Saleem; Rebecca K Martin; Johanna K Morales; Jamie L Sturgill; David R Gibb; Laura Graham; Harry D Bear; Masoud H Manjili; John J Ryan; Daniel H Conrad
Journal:  J Immunol       Date:  2012-06-15       Impact factor: 5.422

Review 3.  Mast cell: insight into remodeling a tumor microenvironment.

Authors:  Jing Liu; Yi Zhang; Jie Zhao; Zhuoshun Yang; Dapeng Li; Foad Katirai; Bo Huang
Journal:  Cancer Metastasis Rev       Date:  2011-06       Impact factor: 9.264

4.  Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice.

Authors:  Eric C Cheon; Khashayarsha Khazaie; Mohammad W Khan; Matthew J Strouch; Seth B Krantz; Joseph Phillips; Nichole R Blatner; Laura M Hix; Ming Zhang; Kristen L Dennis; Mohammed R Salabat; Michael Heiferman; Paul J Grippo; Hidayatullah G Munshi; Elias Gounaris; David J Bentrem
Journal:  Cancer Res       Date:  2011-01-07       Impact factor: 12.701

5.  Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment.

Authors:  Luca Danelli; Barbara Frossi; Giorgia Gri; Francesca Mion; Carla Guarnotta; Lucia Bongiovanni; Claudio Tripodo; Laura Mariuzzi; Stefania Marzinotto; Alice Rigoni; Ulrich Blank; Mario P Colombo; Carlo E Pucillo
Journal:  Cancer Immunol Res       Date:  2014-10-28       Impact factor: 11.151

6.  Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model.

Authors:  Zhuoshun Yang; Biao Zhang; Dapeng Li; Meng Lv; Chunmei Huang; Guan-Xin Shen; Bo Huang
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

7.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Authors:  Kiavash Movahedi; Martin Guilliams; Jan Van den Bossche; Rafael Van den Bergh; Conny Gysemans; Alain Beschin; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

8.  SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment.

Authors:  Bo Huang; Zhang Lei; Gui-Mei Zhang; Dong Li; Chuanwang Song; Bo Li; Yanyan Liu; Ye Yuan; Jay Unkeless; Huabao Xiong; Zuo-Hua Feng
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

9.  Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

Authors:  Stefano Ugel; Elisa Peranzoni; Giacomo Desantis; Mariacristina Chioda; Steffen Walter; Toni Weinschenk; Jordi C Ochando; Anna Cabrelle; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Cell Rep       Date:  2012-09-06       Impact factor: 9.423
  9 in total
  11 in total

Review 1.  Trial Watch: Adoptively transferred cells for anticancer immunotherapy.

Authors:  Carole Fournier; François Martin; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Lionel Apetoh
Journal:  Oncoimmunology       Date:  2017-08-11       Impact factor: 8.110

Review 2.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 3.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

4.  Mouse IP-10 Gene Delivered by Folate-modified Chitosan Nanoparticles and Dendritic/tumor Cells Fusion Vaccine Effectively Inhibit the Growth of Hepatocellular Carcinoma in Mice.

Authors:  Zixi Hu; Jiaojiao Chen; Sufang Zhou; Nuo Yang; Siliang Duan; Zhenghua Zhang; Jing Su; Jian He; Zhiyong Zhang; Xiaoling Lu; Yongxiang Zhao
Journal:  Theranostics       Date:  2017-05-02       Impact factor: 11.556

5.  Interaction between Tumor-Associated Dendritic Cells and Colon Cancer Cells Contributes to Tumor Progression via CXCL1.

Authors:  Ya-Ling Hsu; Yi-Jen Chen; Wei-An Chang; Shu-Fang Jian; Hsiao-Li Fan; Jaw-Yuan Wang; Po-Lin Kuo
Journal:  Int J Mol Sci       Date:  2018-08-16       Impact factor: 5.923

6.  Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis.

Authors:  Mohammed L Ibrahim; John D Klement; Chunwan Lu; Priscilla S Redd; Wei Xiao; Dafeng Yang; Darren D Browning; Natasha M Savage; Phillip J Buckhaults; Herbert C Morse; Kebin Liu
Journal:  Cell Rep       Date:  2018-12-11       Impact factor: 9.423

Review 7.  Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy.

Authors:  Tongyan Liu; Chencheng Han; Siwei Wang; Panqi Fang; Zhifei Ma; Lin Xu; Rong Yin
Journal:  J Hematol Oncol       Date:  2019-08-28       Impact factor: 17.388

8.  Vam3, a Compound Derived from Vitis amurensis Rupr., Attenuated Colitis-Related Tumorigenesis by Inhibiting NF-κB Signaling Pathway.

Authors:  Lingling Xuan; Rentao Jiang; Zhiyuan Wu; Honggan Yi; Chunsuo Yao; Qi Hou; Chunfeng Qu
Journal:  Front Pharmacol       Date:  2016-09-13       Impact factor: 5.810

Review 9.  Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer.

Authors:  Chao Zhang; Shuo Wang; Yufeng Liu; Cheng Yang
Journal:  Oncotarget       Date:  2016-08-30

Review 10.  Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts.

Authors:  Linda Ziani; Salem Chouaib; Jerome Thiery
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.